Atopic dermatitis with mild to moderate severity Atopic dermatitis, Herbal moisturizer, Herbal cream, 1% Hydrocortisone, Skin barrier, Skin hydration
Conditions
Interventions
A cream containing acetyl hexapeptide-49 plus herbal extracts will be applied on active rash of atopic dermatitis on one side of the body, as determined by randomized allocation of volunteers. The tre
Experimental Drug,Experimental Drug
A cream containing acetyl hexapeptide-49 plus herbal extracts,Hydrocortisone cream and cream base
Sponsors
Department of Dermatology, Faculty of Medicine, Srinakharinwirot University
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age 2-18 years old, 2.Diagnosed with atopic dermatitis according to the UK Working Party diagnostic criteria, 3. Disease severity classified as mild to moderate, based on SCORAD score 0-50, 4. Presence of symmetrical lesions on both sides of the body, assessed by percentage of Body Surface Area (BSA), 5. Participants must be able to attend all scheduled follow-up visits during the study period, 6. Participants and their legal guardians must voluntarily agree to participate and sign the informed consent form prior to enrollment
Exclusion criteria
Exclusion criteria: 1. Use of topical anti-inflammatory medications within 2 weeks prior to enrollment, including topical corticosteroids, topical calcineurin inhibitors (tacrolimus, pimecrolimus), topical phosphodiesterase-4 (PDE-4) inhibitors, 2. Use of systemic anti-inflammatory or immunomodulatory treatments within 4 weeks prior to enrollment, including systemic corticosteroids, systemic immunomodulators (cyclosporine, azathioprine, methotrexate, mycophenolate mofetil), biologic agents (dupilumab), phototherapy, 3. Presence of allergic contact dermatitis, skin infection, or open wounds at the intended treatment site at baseline, 4. History of hypersensitivity or allergy to topical corticosteroids or to products containing plant-derived extracts or mineral components
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of the disease Baseline, week 2, 4, 6, 8, and 12 after treatment modified SCORAD, assessed by physician | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of skin hydration Baseline, week 2, and week 4 Corneometer CM825,Rate of transepidermal water loss Baseline, week 2, and week 4 TEWA meter,Patient satisfaction of the treatment Week 4 Visual analog scale (VAS),Median time to disease relapse Week 6, 8, and 12 modified SCORAD, assessed by physician | — |
Countries
Thailand
Contacts
Public ContactMontri Udompataikul
Department of Dermatology, Faculty of Medicine, Srinakharinwirot university
Outcome results
None listed